Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448 · View on ClinicalTrials.gov ↗
Study Summary
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG LY2880070
Study Locations (16)
Other
- General Hospital Zadar — Zadar
- University Hospital Centre Zagreb — Zagreb
- Centrum Onkologii im. prof. F. Łukaszczyka — Bydgoszcz
- Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz — Gdansk
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o. — Krakow
- Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o. — Krakow
Quebec
- Centre Hospitalier de l'Université de Montréal — Montreal
- Jewish General Hospital — Montreal
- McGill University Health Centre — Montreal
Alberta
- Tom Baker Cancer Centre — Calgary
- Cross Cancer Institute — Edmonton
Ontario
- Ottawa Hospital Cancer Centre — Ottawa
- University Health Network - Princess Margaret Hospital — Toronto
Massachusetts
- Dana Farber Cancer Institute — Boston
Michigan
- Karmanos Cancer Institute — Detroit
British Columbia
- BC Cancer Agency — Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2016-05-16 |
| Est. Completion | 2025-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02632448
The ClinicalTrials.gov registry entry for NCT02632448 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperas Pharma, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which Gemcitabine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02632448 reports 16 study locations spanning 7 distinct geographic areas — top geographies include Other, Quebec, Alberta. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02632448 about?
NCT02632448 is a clinical study titled "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer". The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT02632448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2016-05-16. Estimated completion is 2025-04-14.
What conditions does trial NCT02632448 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02632448?
The interventions under investigation include: Gemcitabine (DRUG), LY2880070 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02632448?
This trial is sponsored by Esperas Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02632448 being conducted?
This trial has 16 study locations across Massachusetts, Michigan, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.